



Vivimed

Date: February 13, 2012

To

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1, G Block

Bandra Kurla Complex, Bandra (East)

Mumbai – 400051

Dear Sir/Madam,

Subject : Outcome of Board Meeting

Ref. : Clause 41 of Listing Agreement


With reference to captioned subject and pursuant to Clause 41 of Listing Agreement entered into with the Stock Exchange, we are hereby forwarding unaudited Stand Alone and Consolidated Financial Results for the quarter and nine months ended December 31, 2011 approved by the Board of Directors at their meeting held on February 13,, 2012

Highlights of Stand Alone Results are :

- YoY Sales up by ₹ 909 million to ₹ 2918 million an increase of 45.24%
- YoY EBDITA up by ₹ 191 million to ₹ 611 million an increase of 45.37%
- YoY Profit after Tax up by ₹ 66 million to ₹ 296 million an increase of 28.70%

Highlights of Consolidated Results are :

- YoY Sales up by ₹ 1210 million to ₹ 4173 million an increase of 40.83%
- YoY EBDITA up by ₹ 225 million to ₹ 858 million an increase of 35.54%
- YoY Profit after Tax up by ₹ 42 million to ₹ 408 million an increase of 11.44%





Vivimed

This is for your information and record.

Thanking You,

For **VIVIMED LABS LIMITED**


SANTOSH VARALWAR

MANAGING DIRECTOR & CEO



Encl : As Above

VIVIMED LABS LIMITED
STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED DECEMBER 31st, 2011

Particulars	3 Months ended		9 Months ended		12 Months Audited
	Unaudited		Unaudited		
	31-12-11	31-12-10	31-12-11	31-12-10	
1. (a) Net Sales/Income from Operations	927.56	858.07	2,917.94	2,009.58	3,098.10
(b) Other Operating Income	0.94	0.06	2.59	0.29	2.87
Total Income (a + b)	928.50	858.13	2,920.53	2,009.88	3,100.97
2. Expenditure	758.31	701.74	2,369.59	1,616.36	2,594.97
a. (Increase) / decrease in stock in trade and work in progress	(19.91)	(30.48)	(82.82)	(46.18)	(44.50)
b. Consumption of Raw Materials	558.10	597.72	1,817.75	1,288.57	1,988.45
c. Purchase of Traded Goods	-	-	-	-	-
d. Employee Cost	28.88	28.89	82.31	63.37	105.39
e. Depreciation	20.98	8.88	59.89	26.65	50.31
f. Other Expenditure	170.25	96.72	492.46	283.94	495.33
8. Total	758.31	701.74	2,369.59	1,616.36	2,594.97
3. Profit from Operations before Other Income, Interest and Exceptional items (1 - 2)	170.19	156.39	550.94	393.52	506.00
4. Other Income	-	-	-	-	-
5. Profit before Interest and Exceptional items (3 + 4)	170.19	156.39	550.94	393.52	506.00
6. Interest	51.96	38.09	180.30	109.36	176.31
7. Profit after Interest but before Exceptional items (5 - 6)	118.23	118.30	370.64	284.16	329.69
8. Exceptional items	-	-	-	-	-
9. Profit (+) / Loss (-) from ordinary activities before Tax (7 + 8)	118.23	118.30	370.64	284.16	329.69
10. Tax Expenses	23.66	27.53	74.16	53.68	52.05
11. Net Profit (+) / Loss (-) from ordinary activities after Tax (9 - 10)	94.57	90.77	296.48	230.48	277.64
12. Extraordinary Items (net of tax expense Rs.....)	-	-	-	-	-
13. Net Profit(+) / Loss(-) for period (11 - 12)	94.57	90.77	296.48	230.48	277.64
14. Paid-up Equity Share Capital (Face value of Rs 10/- each)	139.34	101.64	139.34	101.64	101.64
15. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-
16. Earning Per Share(EPS)					
a. Basic EPS before extraordinary items for the period, for the year to date and for the previous year	6.79	8.93	21.28	22.68	27.32
b. Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year	5.89	7.79	18.46	19.78	23.87
17. Public Shareholding					
- Number of shares	78,57,899	50,44,410	78,57,899	50,44,410	50,46,200

(INR in mm)



- Percentage of shareholding							
18. Promoters and Promoter Group Shareholding **							
a) Pledged / Encumbered							
-	Number of shares						
-	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	10,52,455	10,52,455	10,52,455	10,52,455	10,52,455	10,52,455
-	Percentage of shares (as a % of the total share capital of the company)	17.32%	20.56%	17.32%	20.56%	20.56%	20.56%
b) Non - encumbered							
-	Number of shares						
-	Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	50,23,588	40,67,151	50,23,588	40,67,151	40,65,361	
-	Percentage of shares (as a % of the total share capital of the company)	82.68%	79.44%	82.68%	79.44%	79.44%	
		36.06%	40.02%	36.06%	40.02%	40.00%	

1. The above Standalone Results for the Quarter ended December 31, 2011 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on February 13, 2012.
2. During the quarter ended December 31, 2011 company has not received any investor's complaint. No complaint was pending at the beginning of the quarter or lying unsold at the end of the quarter.
3. During the quarter under review the Company has allotted 1,490,000 Equity Shares on Conversion of Warrants.
4. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com.
5. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.
6. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

Place: Hyderabad
Date: 13/02/2012

For VIVIMED LABS LIMITED
(SANTOSH VARAIWAR)
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED
CONSOLIDATED UN-AUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED DECEMBER 31st, 2011

Particulars	3 Months ended		9 Months ended		12 Months Audited
	Unaudited		Unaudited		
	31-12-11	31-12-10	31-12-11	31-12-10	
1. (a) Net Sales/Income from Operations	1,680.11	1,055.86	4,172.54	2,962.53	4,160.01
(b) Other Operating Income	15.84	0.68	17.82	1.08	9.33
Total Income (a + b)	1,695.95	1,056.55	4,190.36	2,963.61	4,169.34
2. Expenditure	1,432.83	829.55	3,465.66	2,386.46	3,410.76
a. (Increase) / decrease in stock in trade and work in progress	(71.76)	(73.39)	(203.74)	(74.78)	(45.91)
b. Consumption of Raw Materials	895.87	681.76	2,404.84	1,823.31	2,415.58
c. Purchase of Traded Goods	-	-	-	-	-
d. Employee Cost	83.56	65.03	203.46	163.74	199.67
e. Depreciation	68.99	15.42	133.32	55.77	91.45
f. Other Expenditure	456.16	140.73	927.78	418.42	749.97
g. Total	1,432.83	829.55	3,465.66	2,386.46	3,410.76
3. Profit from Operations before Other Income, Interest and Exceptional items (1 - 2)	263.12	226.99	724.70	577.16	758.58
4. Other Income	-	-	-	-	-
5. Profit before Interest and Exceptional items (3 + 4)	263.12	226.99	724.70	577.16	758.58
6. Interest	58.58	60.18	202.76	135.58	205.96
7. Profit after Interest but before Exceptional items (5 - 6)	204.54	166.81	521.94	441.57	552.62
8. Exceptional items	-	-	-	-	-
9. Profit (+) / Loss (-) from ordinary activities before Tax (7 + 8)	204.54	166.81	521.94	441.57	552.62
10. Tax Expenses	44.01	33.67	113.53	75.00	64.31
11. Net Profit (+) / Loss (-) from ordinary activities after Tax (9 - 10)	160.53	133.14	408.41	366.58	488.32
12. Extraordinary Items (net of tax expense Rs....)	-	-	-	-	-
13. Net Profit(+) / Loss(-) for period (11 - 12)	160.53	133.14	408.41	366.58	488.32
14. Paid-up Equity Share Capital (Face value of Rs 10/- each)	139.34	101.64	139.34	101.64	101.64
15. Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year					
16. Earning Per Share (EPS)					
a. Basic EPS before extraordinary items for the period, for the year to date and for the previous year	11.52	13.10	29.31	36.07	48.04
b. Diluted EPS after Extraordinary items for the period, for the year to date and for the previous year	-	11.42	-	31.45	41.90
17. Public Shareholding					
- Number of shares	78,57,899	50,44,410	78,57,899	50,44,410	50,46,200
- Percentage of shareholding	56.39%	49.63%	56.39%	49.63%	49.65%

SEAL

LABS LIMITED

100



17

18. Promoters and Promoter Group Shareholding **

a) Pledged / Encumbered					
- Number of shares	10,52,455	10,52,455	10,52,455	10,52,455	10,52,455
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	17.32%	20.56%	17.32%	20.56%	20.56%
- Percentage of shares (as a % of the total share capital of the company)	7.55%	10.35%	7.55%	10.35%	10.36%
b) Non - encumbered					
- Number of shares	50,23,588	40,67,151	50,23,588	40,67,151	40,65,361
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	82.68%	79.44%	82.68%	79.44%	79.44%
- Percentage of shares (as a % of the total share capital of the company)	36.06%	40.02%	36.06%	40.02%	40.00%

1. The above Consolidated Results for the Quarter ended December 31, 2011 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on February 13, 2012.

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard-21 issued by ICAI, New Delhi. Consolidated Results are combined numbers of Vivimed Labs Limited and its wholly owned subsidiaries, (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Selen Private Limited, (iv) Octantis Nobel Labs Private Limited, (v) Vivimed Holdings Limited and their step down subsidiary Vivimed Labs Europe Limited & (vi) Vivimed Labs Mauritius Limited and their step down subsidiaries, Vivimed Labs UK Limited, (b) Vivimed Labs Spain, S.L. (c) Union Quimico Farmaceutica S.A.U., Spain, (d) Uquifa Mexico S.A. de C.V. & (e) Holiday International Limited, UK.

3. Union Quimico Farmaceutica S.A.U. Spain & Uquifa Mexico S.A. de C.V. have been acquired during the quarter. Hence their numbers included in the Consolidated Statements are not for the full quarter.

4. During the quarter ended December 31, 2011 company has not received any investor's complaint. No complaint was pending at the beginning of the quarter or lying unsolved at the end of the quarter.

5. During the quarter under review the Company has allotted 1,490,000 Equity Shares on Conversion of Warrants.

6. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com


7. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

8. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)

MANAGING DIRECTOR & CEO



Place: Hyderabad

Date: 13/02/2012

VIVIMED LABS LIMITED - CONSOLIDATED
SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE
LISTING AGREEMENT


(INR in mm)

Particulars	3 Months ended		9 Months ended		12 Months
	Unaudited	Audited	Unaudited	Audited	Audited
	31-12-11	31-12-10	31-12-11	31-12-10	31-03-11
1. Segment Revenue (Net Sales/Income from each segment should be disclosed under this head)					
a. Speciality Chemicals Business	839.76	789.41	2,553.35	2,299.98	3,162.77
b. Pharma Business	840.35	267.13	1,619.19	663.63	997.24
Total	1,680.11	1,056.55	4,172.54	2,963.61	4,160.01
Less : Inter Segment Revenue	-	-	-	-	-
Net sales / Income from Operations	1,680.11	1,056.55	4,172.54	2,963.61	4,160.01
2. Segment Results(Profit(+)/Loss(-) before tax and interest from each segment					
a. Speciality Chemicals Business	138.29	162.41	450.99	430.56	593.20
b. Pharma Business	124.83	64.58	273.71	146.60	165.38
Total	263.12	226.99	724.70	577.16	758.58
Less: 1. Interest	79.11	60.18	202.76	135.58	205.96
2. Other Un-allocable Expenditure on	-	-	-	-	-
3. Un-allocable Income	-	-	-	-	-
Total Profit Before Tax	184.01	166.81	521.94	441.58	552.61
3. Capital Employed (Segment Assets - Segment Liabilities)					
a. Speciality Chemicals Business	5,511.73	3,582.17	5,511.73	3,582.17	4,783.87
b. Pharma Business	4,195.43	568.74	4,195.43	568.74	595.19
Total	9,707.16	4,150.91	9,707.16	4,150.91	5,379.06

For Vivimed Labs Limited

Place : Hyderabad
Date : 13 / 02 / 2012

(SANTOSH VARADWAR)
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED - STANDALONE
SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE
LISTING AGREEMENT

(INR in mn)

Particulars	3 Months ended		9 Months ended		12 Months ended
	Unaudited	Audited	Unaudited	Audited	Audited
	31-12-11	31-12-10	31-12-11	31-12-10	31-03-11
1. Segment Revenue (net sales/ income from each segment should be disclosed under this head)					
a. Speciality Chemicals Business	669.73	679.02	2,121.54	1,597.76	2,421.30
b. Pharma Business	257.83	179.05	796.40	411.83	676.80
Total	927.56	858.07	2,917.94	2,009.58	3,098.10
Less, Inter Segment Revenue	-	-	-	-	-
Net sales / Income from Operations	927.56	858.07	2,917.94	2,009.58	3,098.10
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment					
a. Speciality Chemicals Business	107.99	105.32	368.29	285.35	387.99
b. Pharma Business	62.20	51.07	182.65	108.17	118.01
Total	170.19	156.39	550.94	393.52	506.00
Less: 1. Interest	51.96	38.09	180.30	109.36	176.31
2. Other Un-allocable Expenditure	-	-	-	-	-
3. Un-allocable Income	-	-	-	-	-
Total Profit Before Tax	118.23	118.30	370.64	284.16	329.69
3. Capital Employed (Segment Assets - Segment Liabilities)					
a. Speciality Chemicals Business	5,896.00	3,434.32	5,896.00	3,434.32	3,495.71
b. Pharma Business	918.85	581.82	918.85	581.82	413.47
Total	6,814.85	4,016.14	6,814.85	4,016.14	3,909.18

For VIVIMED LABS LIMITED



Place : Hyderabad
Date : 13 / 02 / 2012

SANTOSH VARAIWAR
MANAGING DIRECTOR & CEO

